← Back to Screener
IO Biotech, Inc. Common Stock (IOBT)
Price$0.00
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-115.47%
Price vs S&P 500 (4W)-44.26%
VGM Score14.21
Market Capitalization$223,041
All Metrics
Book Value / Share (Quarterly)$0.01
P/TBV (Annual)0.56x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.16
Price vs S&P 500 (YTD)-110.38%
EPS (TTM)$-1.34
10-Day Avg Trading Volume0.36M
EPS Excl Extra (TTM)$-1.34
EPS (Annual)$-1.98
ROI (Annual)-64.65%
Cash / Share (Quarterly)$0.44
ROA (Last FY)-57.12%
EBITD / Share (TTM)$-1.39
Cash Flow / Share (Annual)$-1.25
P/B Ratio0.24x
P/B Ratio (Quarterly)27.78x
Net Income / Employee (Annual)$-1,076,000
Net Interest Coverage (TTM)-1694.25x
ROA (TTM)-180.56%
EPS Incl Extra (Annual)$-1.98
Current Ratio (Annual)3.33x
Quick Ratio (Quarterly)1.72x
3-Month Avg Trading Volume14.62M
52-Week Price Return-99.72%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.39
52-Week High$2.79
EPS Excl Extra (Annual)$-1.98
26-Week Price Return-99.54%
Quick Ratio (Annual)3.18x
13-Week Price Return-99.05%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.01x
Enterprise Value$-13.78M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.91
3-Month Return Std Dev394.54%
Net Income / Employee (TTM)$-1,104,400
ROE (Last FY)-64.65%
Net Interest Coverage (Annual)-7.29x
EPS Basic Excl Extra (Annual)$-1.98
Total Debt / Equity (Quarterly)18.29x
EPS Incl Extra (TTM)$-1.34
ROI (TTM)-355.80%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$4.82
Price vs S&P 500 (52W)-127.93%
Year-to-Date Return-99.44%
5-Day Price Return9.68%
EPS Normalized (Annual)$-1.98
ROA (5Y Avg)-92.05%
Month-to-Date Return-29.17%
Cash Flow / Share (TTM)$-2.33
EBITD / Share (Annual)$-2.10
LT Debt / Equity (Quarterly)18.29x
EPS Basic Excl Extra (TTM)$-1.34
P/TBV (Quarterly)0.49x
P/B Ratio (Annual)1.29x
Book Value / Share (Annual)$0.71
Price vs S&P 500 (13W)-108.80%
Beta0.02x
Revenue / Share (TTM)$0.00
ROE (TTM)-465.36%
52-Week Low$0.00
mGradeF
vgmGradeF
Show chart for
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
2.60
2.60
2.50
2.50
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
IOBTIO Biotech, Inc. Common Stock | — | — | F | $0.00 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
IO Biotech is a clinical-stage biopharmaceutical company developing cancer vaccines using its proprietary T-win technology platform. The company's approach targets multiple immunosuppressive pathways to enhance the immune system's ability to recognize and attack cancer cells. This dual-pathway targeting strategy aims to overcome a key mechanism by which tumors evade immune response.